Bridge Neurotech, Butterfly Network Announce Non-Invasive BCI Partnership

Bridge Neurotech and Butterfly Network have announced a partnership to develop a fully non-invasive brain-computer interface, according to a TradingView item that carried the disclosure.

The two companies named their collaboration in a brief public statement. No direct quotations from executives, technical specifications, financial terms, or development timelines appear in the source reviewed here. That absence matters for clinical neurophysiology readers, who typically evaluate BCI claims through specific parameters: recording modality, montage, channel count, sampling rate, target patient population, and regulatory pathway.

For this announcement, the operative word is fully non-invasive. That phrase distinguishes the planned device from intracortical BCI programs that depend on surgically implanted electrode arrays, and from electrocorticography (ECoG) approaches that require craniotomy or subdural electrode placement. A fully non-invasive system, by definition, breaches neither skin nor skull.

Why "fully non-invasive" is a specific claim

Published non-invasive BCI work in humans has largely relied on one of four recording modalities:

• Scalp EEG, typically with high-density montages of 64 to 256 channels
• Magnetoencephalography (MEG), which localizes sources through magnetic fields
• Functional near-infrared spectroscopy (fNIRS), which measures hemodynamic responses
• Transcranial Doppler or focused ultrasound, which uses acoustic signals

Each modality carries documented trade-offs. Scalp EEG scales most easily to consumer hardware but suffers from volume conduction and motion sensitivity. MEG offers better source localization than scalp EEG but requires a magnetically shielded room. fNIRS captures hemodynamic rather than electrical activity, with second-scale latency. Ultrasound-based methods remain investigational for neural recording in humans.

What the TradingView item does not disclose

The source reviewed here does not identify:

• The recording modality the partners intend to use
• Whether the system targets motor decoding, communication, or neuromodulation
• A regulatory pathway (investigational device exemption versus eventual FDA clearance)
• A patient population or intended use
• A timeline for first-in-human studies
• Financial terms of the partnership

Without those details, the announcement reads as a strategic commitment rather than a technical specification.

How the non-invasive BCI field currently performs

Academic groups have demonstrated EEG-based cursor control and typing in human subjects, typically achieving information-transfer rates measured in characters per minute that remain modest compared with intracortical devices. The performance gap between non-invasive and intracortical systems is the central technical hurdle any commercial non-invasive BCI program must address.

That gap has narrowed in recent years through deep-learning decoders trained on large EEG datasets, and through hybrid EEG-fNIRS systems that combine electrical and hemodynamic features. Still, no non-invasive BCI has, to this site's knowledge, demonstrated the bitrates reported by leading intracortical programs.

Regulatory and clinical context

A non-invasive BCI intended for medical use would, in the United States, typically follow a De Novo or 510(k) pathway to FDA clearance, with clinical data establishing safety and effectiveness for a defined indication. Investigational work, including first-in-human studies, would require an investigational device exemption. The TradingView item does not state which pathway the partners intend to pursue, or whether the device is positioned as a medical device at all.

What to watch next

Three concrete disclosures would move this from a commercial announcement to a clinically evaluable claim:

1. A named recording modality, such as scalp EEG with a stated montage or a specific transcranial ultrasound protocol
2. A defined patient population or intended use, for example communication support for amyotrophic lateral sclerosis or motor restoration after stroke
3. A regulatory filing or first-in-human study date with a named institutional review board or test site

Until at least one of those three appears, the partnership should be tracked as a development-stage announcement. Forward movement on any of those points would justify a follow-up report from this site.